Free bases, salts, and polymorphs of IRAK inhibitors
Crystalline forms of IRAK inhibitors address the inadequacies of current MDS and AML treatments by targeting IRAK1 and IRAK4, enhancing treatment efficacy and overcoming resistance mechanisms.
JP2026517747APending Publication Date: 2026-06-02KUROME THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- KUROME THERAPEUTICS INC
- Filing Date
- 2024-04-26
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517747000001_ABST
Abstract
This disclosure provides crystalline free bases and salts of imidazo[1,2-b]pyridazine compounds. In some embodiments, the crystalline imidazo[1,2-b]pyridazine compounds are single crystals. This disclosure also provides methods for treating specific diseases or disorders using the crystalline form. Some embodiments include methods for treating hematopoietic cancer, myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML) using the crystalline form. Additional embodiments provide treatment of diseases using the crystalline form in combination with other therapies, such as cancer therapy.
Need to check novelty before this filing date? Find Prior Art